Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | PDE2A | O00408 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | HPD | P32754 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.38 |
| ▸ | TXNRD3 | Q86VQ6 | 1/20 | 0.38 |
| ▸ | TXNRD2 | Q9NNW7 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | MASP2 | O00187 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL996550 | 0.84 | ALDH1A1 (0.47) | ALDH1A1KDM4EMAPK1MAPTGAA | |
| SCHEMBL996773 | 0.81 | GAA (0.43) | ALDH1A1KDM4EMAPK1MAPTGAA | |
| SCHEMBL995628 | 0.80 | FEN1 (0.44) | ALDH1A1KDM4EMAPTPDE2APKM | |
| SCHEMBL995605 | 0.77 | ALDH1A1 (0.45) | ALDH1A1KDM4EMAPK1MAPTGAA | |
| SCHEMBL5835785 | 0.75 | STAT3 (0.52) | ALDH1A1MAPTMEN1PKMKMT2A | |
| SCHEMBL996760 | 0.74 | GAA (0.45) | ALDH1A1KDM4EMAPK1MAPTGAA | |
| SCHEMBL995498 | 0.74 | ALDH1A1 (0.46) | ALDH1A1KDM4EMAPK1MAPTGAA | |
| SCHEMBL5835729 | 0.73 | ALDH1A1 (0.51) | ALDH1A1MAPTMEN1PKMKMT2A | |
| SCHEMBL996621 | 0.73 | GAA (0.49) | ALDH1A1KDM4EMAPK1MAPTGAA | |
| SCHEMBL23367934 | 0.72 | PDE2A (0.44) | ALDH1A1KDM4EMAPTPDE2AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101273027-B | The macrocyclic hcv inhibitors of hepatitis C virus | JANSSEN R&D IRELAND (IE) | 2015-12-02 | — | — | CN | disclosed |
| EP-1919898-B1 | MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS | TIBOTEC PHARM LTD (IE) | 2011-01-26 | — | — | EP | disclosed |
| EP-1919898-B1 | MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS | TIBOTEC PHARM LTD (IE) | 2011-01-26 | — | — | EP | disclosed |
| US-7666834-B2 | Macrocyclic inhibitors of hepatitis C virus | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2010-02-23 | — | — | US | disclosed |
| US-7666834-B2 | Macrocyclic inhibitors of hepatitis C virus | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2010-02-23 | — | — | US | disclosed |
| US-7666834-B2 | Macrocyclic inhibitors of hepatitis C virus | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2010-02-23 | — | — | US | disclosed |
| US-20090105302-A1 | Macrocylic Inhibitors of Hepatitis C Virus | JANSSEN SCIENCES IRELAND UC (IE) | 2009-04-23 | — | — | US | disclosed |
| US-20090105302-A1 | Macrocylic Inhibitors of Hepatitis C Virus | JANSSEN SCIENCES IRELAND UC (IE) | 2009-04-23 | — | — | US | disclosed |
| US-20090105302-A1 | Macrocylic Inhibitors of Hepatitis C Virus | JANSSEN SCIENCES IRELAND UC (IE) | 2009-04-23 | — | — | US | disclosed |
| CN-101273027-A | Macrocyclic inhibitors of hepatitis C virus | TIBOTEC PHARM LTD (IE) | 2008-09-24 | — | — | CN | disclosed |
| EP-1919898-A1 | MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS | Tibotec Pharmaceuticals Ltd. (IE) | 2008-05-14 | — | — | EP | disclosed |
| WO-2007014922-A1 | MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2007-02-08 | — | — | WO | disclosed |
| WO-2007014922-A1 | MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2007-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105302-A1 | Macrocylic Inhibitors of Hepatitis C Virus | HCCS, CBR1, CYP2B6 | ALDH1A1 2716/4885KDM4E 3456/4885MAPK1 689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.